Sommario
Gli adenomi ipofisari TSH-secernenti (TSHomi) rappresentano una rara causa di ipertiroidismo, in cui la secrezione di TSH è svincolata dal normale feedback degli ormoni tiroidei. I segni, sintomi e i dati biochimici nei pazienti con TSHoma sono in gran parte sovrapponibili a quelli osservati nella sindrome da resistenza agli ormoni tiroidei (RTH). La terapia di prima linea dei TSHomi è quella chirurgica, mentre gli analoghi della somatostatina sono efficaci nel normalizzare la secrezione ormonale nei pazienti non guariti dopo chirurgia o non candidabili all’approccio chirurgico.
This is a preview of subscription content, log in via an institution to check access.
Bibliografia
Ónnestam L, Berinder K, Burman P et al. (2013) National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 98:626–635
Beck-Peccoz P, Persani L, Mannavola D et al. (2009) Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 23:597–606
Beck-Peccoz P, Lania A, Persani L (2016) TSH-producing adenomas. In: Jameson LJ, DeGroot LJ (eds) Endocrinology, adult and pediatric, II, 7th edn. Saunders Elsevier, Philadelphia, pp 266–274
Teramoto A, Sanno N, Tahara S et al. (2004) Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment. Acta Neuropathol 2004:108–147
Perticone F, Pigliaru F, Mariotti S et al. (2015) Is the incidence of differentiated thyroid cancer increased in patients with thyrotropin-secreting adenomas? Report of three cases from a large consecutive series. Thyroid 25(4):417–424
Koulouri O, Moran C, Halsall D et al. (2013) Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract Res Clin Endocrinol Metab 27:745–762
Beck-Peccoz P, Lania A, Beckers A et al. (2013) European Thyroid Association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2:76–82
Kobayashi S, Yoshimura Noh J, Shimizu T et al. (2017) A case of familial dysalbuminemic hyperthyroxinemia (FDH) in Japan: FDH as a possible differential diagnosis of syndrome of inappropriate secretion of thyroid-stimulating hormone (SITSH). Endocr J 64(2):207–212
Gurnell M, Visser TJ, Beck-Peccoz P et al. (2016) Resistance to thyroid hormone. In: Jameson LJ, DeGroot LJ (eds) Endocrinology, adult and pediatric, II, 6th edn. Saunders Elsevier, Philadelphia, pp 1648–1655
Malchiodi E, Profka E, Ferrante E et al. (2014) Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab 99:2069–2076
Gatto F, Grasso LF, Nazzari E et al. (2015) Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: might somatostatin analogs have a role as first-line therapy? Pituitary 18:583–591
Gatto F, Barbieri F, Gatti M et al. (2012) Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clin Endocrinol (Oxf) 76:407–414
Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228–252
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflitto di interesse
Gli autori Andrea Lania e Federico Gatto dichiarano di non avere conflitti di interesse.
Consenso informato
Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.
Studi sugli animali
Gli autori di questo articolo non hanno eseguito studi sugli animali.
Additional information
Proposto da Andrea Lania.
Materiale elettronico supplementare
Rights and permissions
About this article
Cite this article
Lania, A., Gatto, F. Approccio diagnostico e terapeutico agli adenomi ipofisari TSH-secernenti. L'Endocrinologo 19, 191–195 (2018). https://doi.org/10.1007/s40619-018-0456-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40619-018-0456-x